Trials / Recruiting
RecruitingNCT06528314
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,150 (estimated)
- Sponsor
- Akero Therapeutics, Inc · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Efruxifermin | Administered by subcutaneous injection |
| DRUG | Placebo | Administered by subcutaneous injection |
Timeline
- Start date
- 2024-09-04
- Primary completion
- 2029-09-01
- Completion
- 2029-10-01
- First posted
- 2024-07-30
- Last updated
- 2026-03-13
Locations
316 sites across 19 countries: United States, Argentina, Australia, Brazil, Canada, Chile, France, Germany, India, Israel, Italy, Mexico, Poland, Puerto Rico, South Korea, Spain, Switzerland, Turkey (Türkiye), United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06528314. Inclusion in this directory is not an endorsement.